Taylor & Francis is pleased to invite you to submit your work to an upcoming Article Collection exploring the “Targeted therapies and antibody-drug conjugates (ADCs) in malignant hematology: offering hope to patients with challenging conditions” to the journal Expert Review of Hematology.
By harnessing the power of molecular profiling and innovative drug delivery systems, targeted therapies and ADCs are revolutionizing the way conditions such as leukemia, lymphoma and multiple myeloma are treated, bringing personalized medicine to the forefront of hematologic care.
This Article Collection explores the science, breakthroughs, and patient impact of these transformative therapies. From the latest clinical trials to real-world applications, these articles delve into the mechanisms behind ADCs, the promise of precision oncology and the challenges of accessibility and affordability.
Whether you’re a clinician, researcher or advocate, this collection provides a compelling look at how targeted therapies are changing the narrative for patients with malignant hematologic conditions, offering hope where it was once scarce.
If you are interested in contributing, or would like to learn more, then please reach out to the Commissioning Editor, Reegan Burnell-Clarke, who will be happy to assist.